West Nile-Innovator+EWT (Canada)

Manufacturer: Wyeth Animal Health

Encephalomyelitis-west Nile Virus Vaccine

Eastern and Western, Killed Virus

Tetanus Toxoid

West Nile-Innovator+EWT Indications

For intramuscular vaccination of healthy horses as an aid in the prevention of viremia caused by West Nile virus, and as an aid in the prevention of equine encephalomyelitis due to Eastern and Western viruses, and tetanus. Efficacy of the West Nile fraction was demonstrated in horses that received two doses of the vaccine and were challenged one year post-vaccination with West Nile Virus. The vaccine protected 95% of the vaccinates against infection, while 82% of the controls were viremic.

Dose

Horses, inject one 1 mL dose intramuscularly using aseptic technique. Administer a second 1 mL dose 3 to 4 weeks after the first dose. A 1 mL booster dose should be given annually. Early revaccination may be advisable when horses are faced with an outbreak or with other conditions which might make heavy exposure likely.

West Nile-Innovator+EWT Caution

Store in the dark at 2° to 7°C (35° to 45°F). AVOID FREEZING. SHAKE WELL. Use entire contents when first opened. In some instances, transient local reactions may occur at the injection site. Do not vaccinate within 21 days before slaughter. In case of anaphylactoid reaction, administer epinephrine.

Thimerosal, neomycin and polymyxin B added as preservatives.

For Veterinary Use Only

Patent Pending

© 2004 Fort Dodge Animal Health. All Rights Reserved.

Manufactured by Fort Dodge Animal Health, Fort Dodge, Iowa 50501 U.S.A.

U.S. Vet. License No. 112

Trademarks used under license

Distributed in Canada by Wyeth Animal Health, Division of Wyeth Canada, Guelph, Ontario, Canada

10 mL	10 Doses	C17803A
12 x 1 mL	12 Doses

Nac No.

11573321